Design of iron chelators with therapeutic application.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Dalton Transactions

• Publication date

  2012-05-08

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1039/c2dt12159jPMID 22391807
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Design of clinically useful macromolecular iron chelators

  2011cited by this paper
• The potential application of iron chelators for the treatment of neurodegenerative diseases.

  2011cited by this paper
• Synthesis, iron(III)-binding affinity and in vitro evaluation of 3-hydroxypyridin-4-one hexadentate ligands as potential antimicrobial agents.

  2011cited by this paper
• Desferrithiocin analogue iron chelators: iron clearing efficiency, tissue distribution, and renal toxicity

  2011cited by this paper
• In vitro inhibition of bacterial growth by iron chelators.

  2011cited by this paper
• A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload

  2011cited by this paper
• Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson’s disease after peripheral administration

  2011cited by this paper
• Synthesis, physical-chemical characterisation and biological evaluation of novel 2-amido-3-hydroxypyridin-4(1H)-ones: Iron chelators with the potential for treating Alzheimer's disease.

  2011cited by this paper
• Amido-3-hydroxypyridin-4-ones as iron(III) ligands.

  2010cited by this paper
• Monitoring the efficiency of iron chelation therapy: the potential of nontransferrin‐bound iron

  2010cited by this paper
• Charge states of deferasirox-ferric iron complexes.

  2010cited by this paper
• Design and synthesis of fluorine-substituted 3-hydroxypyridin-4-ones

  2010cited by this paper
• Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.

  2010cited by this paper
• The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores.

  2010cited by this paper
• Identification of a new hexadentate iron chelator capable of restricting the intramacrophagic growth of Mycobacterium avium.

  2010cited by this paper
• Combined iron chelation therapy

  2010cited by this paper
• Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.

  2010cited by this paper
• Chemistry and biology of siderophores.

  2010cited by this paper
• Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias

  2010cited by this paper
• Iron chelation using subcutaneous infusions of diethylene triamine penta-acetic acid (DTPA).

  2009cited by this paper
• Siderophores as drug delivery agents: application of the “Trojan Horse” strategy

  2009cited by this paper
• Influence of non-enzymatic post-translation modifications on the ability of human serum albumin to bind iron. Implications for non-transferrin-bound iron speciation.

  2009cited by this paper
• Long‐term sequential deferiprone–deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial

  2009cited by this paper
• Iron(III) citrate speciation in aqueous solution.

  2009cited by this paper
• Determination of the pKa value of the hydroxyl group in the α-hydroxycarboxylates citrate, malate and lactate by 13C NMR: implications for metal coordination in biological systems

  2009cited by this paper
• Fanconi syndrome due to deferasirox.

  2009cited by this paper
• Fenton chemistry and oxidative stress mediate the toxicity of the β-amyloid peptide in a Drosophila model of Alzheimer’s disease

  2009cited by this paper
• Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease.

  2009cited by this paper
• Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation.

  2008cited by this paper
• Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators

  2008cited by this paper
• Potentiometric, spectrophotometric and calorimetric study on iron(III) and copper(II) complexes with 1,2-dimethyl-3-hydroxy-4-pyridinone.

  2008cited by this paper
• Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation

  2008cited by this paper
• The fenton activity of iron(III) in the presence of deferiprone.

  2008cited by this paper
• Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY‐5Y cells

  2008cited by this paper
• Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.

  2008cited by this paper
• Is the β thalassaemia trait of clinical importance?

  2008cited by this paper
• A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease

  2007cited by this paper
• Selective iron chelation in Friedreich ataxia: biologic and clinical implications.

  2007cited by this paper
• The iron chelator deferasirox protects mice from mucormycosis through iron starvation.

  2007cited by this paper
• Iron chelation beyond transfusion iron overload

  2007cited by this paper
• IN VITRO BLOOD DISTRIBUTION AND PLASMA PROTEIN BINDING OF THE IRON CHELATOR DEFERASIROX (ICL670) AND ITS IRON COMPLEX FE-[ICL670]2 FOR RAT, MARMOSET, RABBIT, MOUSE, DOG, AND HUMAN

  2006cited by this paper
• Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.

  2006cited by this paper
• (S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity.

  2006cited by this paper
• Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences.

  2006cited by this paper
• Chelator-Induced Dispersal and Killing of Pseudomonas aeruginosa Cells in a Biofilm

  2006cited by this paper
• The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy

  2005cited by this paper
• Desketoneoenactin-Siderophore Conjugates for Candida: Evidence of Iron Transport-Dependent Species Selectivity

  2005cited by this paper
• Purging iron from the heart

  2004cited by this paper
• Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats.

  2004cited by this paper
• Redox Properties of the Iron Complexes of Orally Active Iron Chelators CP20, CP502, CP509, and ICL670

  2004cited by this paper
• Complex Formation of ICL670 and Related Ligands with FeIIIand FeII: Complex Formation of ICL670 and Related Ligands with FeIIIand FeII

  2004cited by this paper
• Molecular Shuttle Chelation: The Use of Ascorbate, Desferrioxamine and Feralex-G in Combination to Remove Nuclear Bound Aluminum

  2004cited by this paper
• Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia.

  2003cited by this paper
• Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease.

  2003cited by this paper
• Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis.

  2003cited by this paper
• Rational design of sequestering agents for plutonium and other actinides.

  2003cited by this paper
• Role of deferiprone in chelation therapy for transfusional iron overload.

  2003cited by this paper
• Safety, Tolerability, and Pharmacokinetics of ICL670, a New Orally Active Iron‐Chelating Agent in Patients with Transfusion‐Dependent Iron Overload Due to β‐Thalassemia

  2003cited by this paper
• Current Status of Metals as Therapeutic Targets in Alzheimer's Disease

  2003cited by this paper
• A novel trivalent cation chelator Feralex dissociates binding of aluminum and iron associated with hyperphosphorylated tau of Alzheimer's disease.

  2003cited by this paper
• The metallobiology of Alzheimer's disease.

  2003cited by this paper
• Synthesis and physicochemical assessment of novel 2‐substituted 3‐hydroxypyridin‐4‐ones, novel iron chelators

  2002cited by this paper
• Design of clinically useful iron(III)‐selective chelators

  2002cited by this paper
• The distribution of the anti‐HIV drug, 2′3′‐dideoxycytidine (ddC), across the blood–brain and blood–cerebrospinal fluid barriers and the influence of organic anion transport inhibitors

  2002cited by this paper
• The safety and effectiveness of deferiprone in a large‐scale, 3‐year study in Italian patients

  2002cited by this paper
• Design, synthesis, and evaluation of novel 2-substituted 3-hydroxypyridin-4-ones: structure-activity investigation of metalloenzyme inhibition by iron chelators.

  2002cited by this paper
• Synthesis of feralex a novel aluminum/iron chelating compound.

  2002cited by this paper
• Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial.

  2002cited by this paper
• Protective effects of the sickle cell gene against malaria morbidity and mortality.

  2002cited by this paper
• Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice

  2001cited by this paper
• Chelation therapy in beta-thalassemia: an optimistic update.

  2001cited by this paper
• ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture.

  2001cited by this paper
• Treatment of Alzheimer’s Disease with Clioquinol

  2001cited by this paper
• Chelation therapy in β-thalassemia: An optimistic update☆

  2001cited by this paper
• Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.

  2001cited by this paper
• Systemically administered D-glucose conjugates of 7-chlorokynurenic acid are centrally available and exert anticonvulsant activity in rodents.

  2000cited by this paper
• Biliary and urinary metabolic profiles of 1,2-diethyl-3-hydroxypyridin-4-one (CP94) in the rat.

  2000cited by this paper
• Iron and citric acid: A fuzzy chemistry of ubiquitous biological relevance

  2000cited by this paper
• Synthesis and biological studies of glycosyl dopamine derivatives as potential antiparkinsonian agents.

  2000cited by this paper
• Improving the oral bioavailability of the iron chelator HBED by breaking the symmetry of the intramolecular H-bond network.

  2000cited by this paper
• Chelating Agents

  2000cited by this paper
• Enkephalin glycopeptide analogues produce analgesia with reduced dependence liability.

  2000cited by this paper
• Investigation into the correlation between the structure of hydroxypyridinones and blood-brain barrier permeability.

  1999cited by this paper
• Effects of C-4 stereochemistry and C-4' hydroxylation on the iron clearing efficiency and toxicity of desferrithiocin analogues.

  1999cited by this paper
• Jejunal permeability in humans in vivo and rats in situ: investigation of molecular size selectivity and solvent drag.

  1999cited by this paper
• Deferiprone

  1999cited by this paper
• In Vitro and In Situ Permeability of a 'Second Generation' Hydroxypyridinone Oral Iron Chelator: Correlation with Physico-Chemical Properties and Oral Activity

  1999cited by this paper
• Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase.

  1999cited by this paper
• Synthesis, physicochemical characterization, and biological evaluation of 2-(1'-hydroxyalkyl)-3-hydroxypyridin-4-ones: novel iron chelators with enhanced pFe(3+) values.

  1999cited by this paper
• 4-3,5-BIS(2-HYDROXYPHENYL)-1,2,4-TRIAZOL-1-YL-BENZOIC ACID : A NOVEL EFFICIENT AND SELECTIVE IRON(III) COMPLEXING AGENT

  1999cited by this paper
• Desazadesmethyldesferrithiocin analogues as orally effective iron chelators.

  1999cited by this paper
• Active transport of siderophore-mimicking antibacterials across the outer membrane.

  1999cited by this paper
• HBED: A potential alternative to deferoxamine for iron-chelating therapy.

  1998cited by this paper
• New considerations in the treatment of sickle cell disease.

  1998cited by this paper
• Iron chelators for clinical use.

  1998cited by this paper
• Caco-2 cell permeability of a new (hydroxybenzyl)ethylenediamine oral iron chelator: correlation with physicochemical properties and oral activity.

  1998cited by this paper
• Combined therapy with deferiprone and desferrioxamine

  1998cited by this paper
• Iron Chelators for Thalassaemia

  1998cited by this paper
• A Risk-Benefit Assessment of Iron-Chelation Therapy

  1997cited by this paper
• O-TRENSOX, a New Tripodal Iron Chelator Based on 8-Hydroxyquinoline Subunits: Thermodynamic and Kinetic Studies

  1997cited by this paper

• Natural sideromycins and siderophore-conjugated natural products as inspiration for novel antimicrobial agents.

  2025cites this paper
• Interactions Between Iron Metabolism and the Endocannabinoid System in Bacterial Infections

  2025cites this paper
• A novel quinoxaline-based multifunctional probe: Sensitive and selective naked-eye detection of Fe3+ and fluorescent sensing of Cu2+ and its application

  2024cites this paper
• Modeling ferroptosis in human dopaminergic neurons: Pitfalls and opportunities for neurodegeneration research

  2024cites this paper
• Enhancement of growth media for extreme iron limitation in Escherichia coli

  2024cites this paper
• Skin complications during iron chelation therapy for beta-thalassemia: overview and treatment approach

  2024influential citation
• Comparison of iron deposits removing material from the marine archaeological wood of Nanhai I shipwreck

  2024cites this paper
• Repurposing iron chelators for accurate positron emission tomography imaging tracking of radiometal‐labeled cell transplants

  2024influential citation
• Designing mimosine-containing peptides as efficient metal chelators: Insights from molecular dynamics and quantum calculations.

  2024cites this paper
• Article review: Brazilin as potential anticancer agent

  2024cites this paper
• Chelators as Antineuroblastomas Agents.

  2023cites this paper
• N-Based Polydentate Ligands and Corresponding Zn(II) Complexes: A Structural and Spectroscopic Study

  2023cites this paper
• Steric Blockade of Oxy-Myoglobin Oxidation by Thiosemicarbazones: Structure-Activity Relationships of the Novel PPP4pT Series.

  2023cites this paper
• Efflux systems as a target for anti-biofilm nanoparticles: perspectives on emerging applications

  2023cites this paper
• Recent advances in therapeutical applications of the versatile hydroxypyridinone chelators

  2022cites this paper
• Heterologous Expression and Biochemical Analysis Reveal a Schizokinen-Based Siderophore Pathway in Leptolyngbya (Cyanobacteria)

  2022cites this paper
• Hydroxypyridinone-Based Metal Chelators towards Ecotoxicity: Remediation and Biological Mechanisms

  2022influential citation
• Iron Effects on Clostridioides difficile Toxin Production and Antimicrobial Susceptibilities

  2022cites this paper
• Naked Eye Chemosensor and In Vivo Chelating Activity of Iron (III) By Bromopyridine Quinoxaline (BPQ)

  2022cites this paper
• Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present

  2022cites this paper
• Understanding the Potential and Risk of Bacterial Siderophores in Cancer

  2022cites this paper
• Safety and efficacy of a novel iron chelator (HBED; (N,N′‐Di(2‐hydroxybenzyl)ethylenediamine‐N,N′‐diacetic acid)) in equine (Equus caballus) as a model for black rhinoceros (Diceros bicornis)

  2022cites this paper
• Advances in Evaluation of Antioxidant and Toxicological Properties of Stryphnodendron rotundifolium Mart. in Drosophila melanogaster Model

  2022cites this paper
• Combined administration of membrane-permeable and impermeable iron-chelating drugs attenuates ischemia/reperfusion-induced hepatic injury.

  2022cites this paper
• Hydroxypyrone derivatives in drug discovery: from chelation therapy to rational design of metalloenzyme inhibitors.

  2022cites this paper
• In Vitro and In Vivo Antiamebic Activity of Iron-Targeting Polypyridine Compounds against Enteric Protozoan Parasite Entamoeba histolytica.

  2022cites this paper
• Synthesis, physicochemical characterization and neuroprotective evaluation of novel 1-hydroxypyrazin-2(1H)-one iron chelators in an in vitro cell model of Parkinson's disease

  2022cites this paper
• Diversity in the Interaction of Amino Acid- and Peptide-Based Hydroxamic Acids with Some Platinum Group Metals in Solution

  2022cites this paper
• Redox-Active Metal Ions and Amyloid-Degrading Enzymes in Alzheimer’s Disease

  2021cites this paper
• Intracellular Iron Binding and Antioxidant Activity of Phytochelators

  2021cites this paper
• Antioxidant activity and functional properties of grey mullet (Mugil cephalus) protein hydrolysates

  2021cites this paper
• The Effects of Redox-Active Metal Ions and Amyloid-Degrading Enzymes on the Pathology of Alzheimer's Disease

  2021cites this paper
• Ten Years Progress of Electrical Detection of Heavy Metal Ions (HMIs) Using Various Field-Effect Transistor (FET) Nanosensors: A Review

  2021cites this paper
• Hydroxypyridinones as a Very Promising Platform for Targeted Diagnostic and Therapeutic Radiopharmaceuticals

  2021influential citation
• Chelators for Treatment of Iron and Copper Overload: Shift from Low-Molecular-Weight Compounds to Polymers

  2021cites this paper
• Quercetin attenuates neurotoxicity induced by iron oxide nanoparticles

  2021cites this paper
• Degradable poly(catechin) nanoparticles as a versatile therapeutic agent

  2021cites this paper
• Innovative Therapies for Neuroblastoma: The Surprisingly Potent Role of Iron Chelation in Up-Regulating Metastasis and Tumor Suppressors and Down-Regulating the Key Oncogene, N-myc.

  2021cites this paper
• Cigarette smoke-induced toxicity consequences of intracellular iron dysregulation and ferroptosis.

  2021cites this paper
• Exploiting the Achilles’ Heel of Iron Dependence in Antibiotic Resistant Bacteria with New Antimicrobial Iron Withdrawal Agents

  2021cites this paper
• Nutritional immunity: the impact of metals on lung immune cells and the airway microbiome during chronic respiratory disease

  2021cites this paper
• Iron-withdrawing anti-infectives for new host-directed therapies based on iron dependence, the Achilles’ heel of antibiotic-resistant microbes

  2021cites this paper
• Pyridones in drug discovery: recent advances.

  2021cites this paper
• High Antiproliferative Activity of Hydroxythiopyridones over Hydroxypyridones and Their Organoruthenium Complexes

  2021cites this paper
• Predicting the Thermodynamic Stability of Zirconium Radiotracers.

  2020cites this paper
• Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity.

  2020cites this paper
• Hydroxypyridinone-Based Iron Chelators with Broad-Ranging Biological Activities.

  2020cites this paper
• Pentagalloyl glucose from Schinus terebinthifolia inhibits growth of carbapenem-resistant Acinetobacter baumannii

  2020cites this paper
• Integrated Flow-based System Displaying an In-line Mini Soil Column to Monitor Iron Species in Soils Leachates

  2020cites this paper
• Effectiveness of deferiprone-loaded nanocarrier in experimentally induced rhabdomyolysis: A dose-comparison study.

  2020cites this paper
• A DFT study on the metal ion selectivity of deferiprone complexes

  2020cites this paper
• Practical Management of Iron Overload Disorder (IOD) in Black Rhinoceros (BR; Diceros bicornis)

  2020cites this paper
• Design and evaluation of bi-functional iron chelators for protection of dopaminergic neurons from toxicants

  2020cites this paper
• Designing of alternative polymeric nano-chelator for treatment in acute iron poisoning by molecular imprinting approach

  2020cites this paper
• Reductive Stress, Bioactive Compounds, Redox-Active Metals, and Dormant Tumor Cell Biology to Develop Redox-Based Tools for the Treatment of Cancer

  2020cites this paper
• Synthesis, characterization, biological activity and electrochemistry studies of iron(III) complex with curcumin‐oxime ligand

  2020cites this paper
• A combined molecular dynamics and quantum mechanics study on the interaction of Fe3+ and human serum albumin relevant to iron overload disease

  2020cites this paper
• CN128, a new orally active hydroxypyridinone iron chelator.

  2020cites this paper
• Hydrazones as novel epigenetic modulators: Correlation between TET 1 protein inhibition activity and their iron(II) binding ability.

  2019cites this paper
• New hydrophilic 3-hydroxy-4-pyridinone chelators with ether-derived substituents: Synthesis and evaluation of analytical performance in the determination of iron in waters

  2019cites this paper
• In silico design of mimosine containing peptides as new efficient chelators of aluminum

  2019cites this paper
• Oxidative Metabolism of Iron: Can Something Good for Health be Harmful When it is Supplemented In Excess?

  2019cites this paper
• Iron-Binding and Anti-Fenton Properties of Novel Amino Acid-Derived Cyclic Imide Dioximes

  2019cites this paper
• Smoking‐induced iron dysregulation in the lung

  2019cites this paper
• Iron chelating, reducing and anti-glycation activities of Coleus aromaticus leaves protein

  2019cites this paper
• Anticancer activity of a novel methylated analogue of L-mimosine against an in vitro model of human malignant melanoma

  2019cites this paper
• l‐3,4‐dihydroxyphenylalanine (l‐DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha‐synuclein mouse models of Parkinson's disease

  2019cites this paper
• Synthesis and iron chelating properties of hydroxypyridinone and hydroxypyranone hexadentate ligands.

  2019cites this paper
• The role of mitochondrial labile iron in Friedreich's ataxia skin fibroblasts sensitivity to ultraviolet A† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c8mt00257f

  2019cites this paper
• Synthesis and Study of Multifunctional Cyclodextrin–Deferasirox Hybrids

  2019cites this paper
• Deferiprone: Pan-selective Histone Lysine Demethylase Inhibition Activity and Structure Activity Relationship Study

  2019cites this paper
• Study of the effect of thiourea and N-ethyl groups on antibacterial activity of rhodamine-labeled 3,4-HPO iron chelators against Gram (+/−) bacteria

  2018cites this paper
• The first total synthesis of gobichelin B: a mixed-ligand siderophore of Streptomyces sp. NRRL F-4415.

  2018cites this paper
• Synthesis and characterization of methyl substituted 3-hydroxypyridin-4-ones and their complexes with iron(III)

  2018cites this paper
• Multidentate Ligand Design for the F-Elements

  2018cites this paper
• A new tripodal-3-hydroxy-4-pyridinone for iron and aluminium sequestration: synthesis, complexation and in vivo studies

  2018cites this paper
• The possibility of iron chelation therapy in the presence of different HPOs; a molecular approach to the non-covalent interactions and binding energies

  2018cites this paper
• The interaction of pyridoxal isonicotinoyl hydrazone (PIH) and salicylaldehyde isonicotinoyl hydrazone (SIH) with iron.

  2018cites this paper
• The kinetics of dimethylhydroxypyridinone interactions with iron(iii) and the catalysis of iron(iii) ligand exchange reactions: implications for bacterial iron transport and combination chelation therapies.

  2018cites this paper
• Iron and Copper Intracellular Chelation as an Anticancer Drug Strategy

  2018cites this paper
• An overview on ligands of therapeutically interest

  2018cites this paper
• Modifying aroylhydrazone prochelators for hydrolytic stability and improved cytoprotection against oxidative stress.

  2018cites this paper
• Tuning the Anti(myco)bacterial Activity of 3-Hydroxy-4-pyridinone Chelators through Fluorophores

  2018cites this paper
• A review on iron chelators as potential therapeutic agents for the treatment of Alzheimer’s and Parkinson’s diseases

  2018cites this paper
• Hydroxypyridinone Journey into Metal Chelation.

  2018cites this paper
• The mono(catecholamine) derivatives as iron chelators: synthesis, solution thermodynamic stability and antioxidant properties research

  2018cites this paper
• New tris(dopamine) derivative as an iron chelator. Synthesis, solution thermodynamic stability, and antioxidant research.

  2017cites this paper
• Synthesis and biological evaluation of deferiprone-resveratrol hybrids as antioxidants, Aβ1-42 aggregation inhibitors and metal-chelating agents for Alzheimer's disease.

  2017cites this paper
• Chemical and Biological Aspects of Nutritional Immunity-Perspectives for New Anti-Infectives that Target Iron Uptake Systems.

  2017cites this paper
• A DFT study on the complex formation between desferrithiocin and metal ions (Mg2+, Al3+, Ca2+, Mn2+, Fe3+, Co2+, Ni2+, Cu2+, Zn2+)

  2017cites this paper
• The hydrolytic susceptibility of prochelator BSIH in aqueous solutions.

  2017cites this paper
• Preparation of Nano Triblock Co-polymer for Desferoxiamine Delivery and Cross-Linked Copolymer for Iron Overload Disease

  2017cites this paper
• An Overview of Multifunctional Metal Chelators as Potential Treatments for Neurodegenerative Diseases

  2017cites this paper
• The “Iron”‐y of Iron Overload and Iron Deficiency in Chronic Obstructive Pulmonary Disease

  2017cites this paper
• Klinik Olarak Faydalı Demir Bağlayıcı Ligandların Tasarım Özellikleri

  2017cites this paper
• Chemische und biologische Aspekte von “Nutritional Immunity” – Perspektiven für neue Antiinfektiva mit Fokus auf bakterielle Eisenaufnahmesysteme

  2017cites this paper
• Pyrophosphate functionalized silver nanoparticles for colorimetric determination of deferiprone via competitive binding to Fe(III)

  2017cites this paper
• In vitro antiproliferative study of novel adamantyl pyridin-4-ones

  2017cites this paper
• Hydroxypyridinone Chelators: From Iron Scavenging to Radiopharmaceuticals for PET Imaging with Gallium-68

  2017cites this paper
• Anti-inflammatory effects of a novel iron chelator, DIBI, in experimental sepsis

  2017cites this paper